Clinical Trial Update: A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intravesical nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy for high-grade BCG-unresponsive non-mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma in Situ of the Bladder
• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Adstiladrin (nadofaragene firadenovec) (nadofaragene firadenovec)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | Phase 3 | Status: RECRUITING